Menssen, A., Ashango, A., Alonzo, T., Gerbing, R., Pardo, M., Hsu, F., Lott, L., Dai, F., Cooper, T., Pollard, J., Tarlock, K., Aplenc, R., Meshinchi, S., Brodersen, L., Loken, M., Hudson, C. (2025). FLT3 (CD135) expression in pediatric AML is associated with specific disease characteristics and worse outcome in the setting of sorafenib theraphy: A report from the Children's Oncology Group AAML1031 protocol.. Blood. https://doi.org/10.1182/blood-2025-5256